Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801644 | 0.87 | HTR2B (0.45) | HTR2BSMN1; SMN2ATMNLRP3HTT | |
| SCHEMBL802232 | 0.83 | HTR2B (0.45) | HTR2BSMN1; SMN2ATMHTTLMNA | |
| SCHEMBL801641 | 0.82 | HTR2B (0.44) | HTR2BSMN1; SMN2ATM | |
| SCHEMBL12653336 | 0.77 | NLRP3 (0.41) | HTR2BSMN1; SMN2ATMNLRP3MAPT | |
| SCHEMBL25803289 | 0.77 | KDM4E (0.37) | SMN1; SMN2ATMNLRP3MAPTALDH1A1 | |
| SCHEMBL25803299 | 0.74 | NOS3 (0.36) | MAPTALDH1A1HPGDMEN1LMNA | |
| SCHEMBL15233169 | 0.74 | STAT3 (0.39) | HTR2BNLRP3MAPTNPSR1ALDH1A1 | |
| SCHEMBL30041552 | 0.73 | EHMT2 (0.34) | NLRP3MEN1KMT2AHTR2CNOS3 | |
| SCHEMBL12653938 | 0.72 | STAT3 (0.38) | HTR2BNLRP3MAPTNPSR1ALDH1A1 | |
| SCHEMBL13108043 | 0.68 | HTR2B (0.43) | HTR2BSMN1; SMN2ATMNLRP3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | HTR2B 3477/4885SMN1; SMN2 4008/4885ATM 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.